GlassScriptPhysician profile
Lee Stuart Diamond
NPI 1497330773
$1,330.49
in general payments reported to CMS, 2019-2025
16 companies · $255 in 2025
The $255 reported for 2025 was less than what a typical Psychiatric/Mental Health (Nurse Practitioner) provider received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $220 · 2023: $558 · 2024: $297 · 2025: $255.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,063 · Education: $47.48.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,063.30 |
| Education | $47.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $264.96 | 2022-2024 | Caplyta |
| Vanda Pharmaceuticals INC. | $203.89 | 2022-2024 | Fanapt |
| Neurocrine Biosciences, INC. | $153.26 | 2023-2024 | Ingrezza |
| Janssen Pharmaceuticals, INC | $129.00 | 2025 | Spravato |
| Abbvie INC. | $116.06 | 2022-2023 | |
| E.R. Squibb & Sons, L.L.C. | $106.49 | 2025 | Cobenfy |
| Otsuka America Pharmaceutical, INC. | $88.80 | 2022-2024 | Rexulti, Abilify Asimtufii |
| Exact Sciences Corporation | $43.25 | 2024-2025 | Cologuard Collection Kit |
| Lundbeck LLC | $38.45 | 2023-2024 | Rexulti |
| Alkermes, INC. | $35.07 | 2022-2023 | Aristada, Lybalvi |
| Axsome Therapeutics, INC. | $34.95 | 2023 | Auvelity |
| Idorsia Pharmaceuticals US INC | $31.90 | 2023-2024 | Quviviq |
| Sunovion Pharmaceuticals INC. | $24.27 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $22.22 | 2022 | |
| Acadia Pharmaceuticals INC | $22.18 | 2023 | Nuplazid |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $15.74 | 2023 | Qelbree |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lee Diamond listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.